Details of the Drug Combinations

General Information of This Drug (ID: DMPW5SB)

Drug Name

BAY 86-9766 DMPW5SB

Synonyms

923032-37-5; RDEA119; BAY 869766; RDEA 119; UNII-JPX07AFM0N; RDEA-119; Refametinib (RDEA119, Bay 86-9766); JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib [INN]; 923032-38-6; BAY-869766; BAY 8697661; 3e8n; Refametinib R enantiomer; Refametinib (RDEA119); SCHEMBL345333

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bay 86-9766 + Panobinostat	DCCZ7J3	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gemcitabine + Bay 86-9766	DCW33WB	Gemcitabine	Neoplasms	[3]
Regorafenib + Bay 86-9766	DCJG7WO	Regorafenib	Neoplasms	[4]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7942).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT01764828) BAY86-9766 Plus Gemcitabine Phase I Study in Asian
4	ClinicalTrials.gov (NCT02168777) Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer